drugset / Trial / NCT06788236
Study of Efficacy and Safety of AVTR101 in Sarcopenic Elderly
Phase 2
Terminated
100 enrolled
Aventi Biotechnology Inc.
Ajou University School of Medicine · collabAsan Medical Center · collabSMG-SNU Boramae Medical Center · collabSeoul National University Bundang Hospital · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The goal of this clinical trial is to primarily evaluate the efficacy of AVTR101 to placebo on physical performance in sarcopenia patients. Participants will: Take AVTR101 or a placebo three times daily for 12 weeks Visit the clinic once every 4 weeks for checkups and tests
Timeline
- Start
- 2022-05-23
- Primary completion
- 2024-06-14
- Completion
- 2024-09-19
Outcome
Outcome not reported
Stopped (Enrollment): “Due subject enrollment delay and to secure expiration of the test drug, it was necessary to minimize the subject enrollment period. In addition, it was deemed advantageous to increase the overall efficiency of the clinical program.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AVTR101 | Unknown | 120 mg | — |